It may not be a good idea to buy GlaxoSmithKline plc (LON: GSK) for the next divorce

GlaxoSmithKline plc (LON: GSK) to ex-dividend trading in the next three days. This means that investors who buy shares on or after February 18 will not receive the divorce, which will be paid on April 8th.

The next installment payment at GlaxoSmithKline is £ 0.23 per share in the UK, and in the last 12 months, the company has paid £ 0.80 per share in the UK. Measuring the value of last year’s payments, it can be seen that GlaxoSmithKline has a 6.3% slump yield on the current installment price of £ 12.78. Shares contribute significantly to investment returns for long-term investors, but only if the dividend is paid for. So we need to examine whether GlaxoSmithKline can pay for its share, and whether the split could grow.

See our latest analysis for GlaxoSmithKline

Shares are usually paid out of a company’s income, so if a company pays out more than they earned, its share is usually at higher risk to be cut. GlaxoSmithKline paid more than half (69%) of its earnings last year, which is a consistent pay ratio for most companies. But cash flow is usually more important than profit for assessing the stability of shares, so we should always make sure that the company has generated enough money to pay for its share. It paid out more than half (53%) of the free cash flow in the past year, which is within the average range for most companies.

It is encouraging to see that the sector is covered by both profit and cash flow. This usually indicates that the divide is stable, as long as employment does not fall sharply.

Click here to see the company’s pay ratio, as well as analysts ’estimates of future shares.

LSE: GSK Historical Loyalty 14 February 2021

Have salaries and shares grown?

Businesses with declining employment are struggling from a segregation perspective. If earnings fall and the company manages to cut its share, investors could look at the value of the investment going up in a fog. Readers will then understand, why we are concerned to see that GlaxoSmithKline ‘s earnings per share have fallen 7.9% a year over the last five years. When earnings per share fall, the maximum amount of shares payable also falls.

The main way most investors assess the prospects of a company’s shares is by examining the historical rate of province growth. GlaxoSmithKline has averaged 2.7% annual share growth over the past 10 years. Growing the dividend pay ratio while earnings decline can yield good results for a while, but it is worth keeping an eye on when the company can no longer increase the pay ratio – because then the music stops.

Last takeaway

Is GlaxoSmithKline on what it is taking to maintain the share payments? While earnings per share are declining, it is encouraging to see that at least GlaxoSmithKline ‘s share appears to be stable, with pay and cash flow ratios that are within reasonable limits. It’s not an attractive mix from a separation perspective, and we’re likely to give this one a go at this point.

So if you are still interested in GlaxoSmithKline despite its seriousness in terms of stock features, you should be aware of some of the risks faced by this stock. For example, we found 1 warning sign for GlaxoSmithKline that we suggest you consider before investing in the business.

We wouldn’t recommend just buying the first stock of shares you see, though. Here is a list of interesting stock shares with a yield of more than 2% and an upcoming share.

If you decide to trade on GlaxoSmithKline, use the platform * at the lowest cost rated # 1 Overall by Barron’s, Interactive Brokers. Trading stocks, options, futures, forex, bonds and currencies on 135 markets, all from a single unified account.

This article by Simply Wall St is generic in nature. It is not a recommendation to buy or sell any stock, and it does not take into account your goals, or your financial situation. We aim to provide you with focused long-term analysis guided by baseline data. Please note that our analysis may not affect the most recent price-sensitive or qualitative product statements. Simply put, Wall St has no position in any of the stocks listed.
*Interactive Brokers rated lowest cost by Online Annual Review 2020

Do you have any feedback on this article? Concerned about content? contact us with us directly. Alternatively, email the editorial team (at)